Open AccessReal-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
Author(s) -
Nicole Engel-Nitz,
Michael P. Johnson,
Scott Bunner,
Kellie Ryan
Publication year - 2020
Publication title -
journal of managed care and specialty pharmacy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.126
H-Index - 63
eISSN - 2376-1032
pISSN - 2376-0540
DOI - 10.18553/jmcp.2020.26.6.729
Subject(s) - medicine , lung cancer , incidence (geometry) , oncology , retrospective cohort study , adverse effect , cohort , cancer , population , cohort study , health care , environmental health , physics , optics , economics , economic growth
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer in the United States. Immunotherapies and cytotoxic chemotherapies used to treat advanced NSCLC carry a substantial risk of adverse events (AEs), but real-world data on the incidence and costs associated with the unique AE profiles of these treatments are sparse.